Drug Search Results
More Filters [+]

Laropiprant

Alternative Names: laropiprant, mk-0524b, mk-0524, mk0524, mk 0524
Latest Update: 2023-08-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CRTH2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hungary | India | Ireland | Italy | New Zealand | Russia | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Laropiprant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemia|Hyperlipidemia|Type 2 Diabetes|Coronary Artery Disease|Atherosclerosis|Inflammation|Myocardial Ischemia|Oxidative Stress

Phase 3: Dyslipidemia|Hypercholesterolemia|Type 2 Diabetes|Stroke|Hyperlipidemia|Myocardial Infarction|Intermittent Claudication|Peripheral Arterial Disease|Coronary Disease|Coronary Artery Disease|Hyperlipoproteinemias|Lipidoses|Hyperlipoproteinemia Type V|Hyperlipoproteinemia Type II|Myocardial Ischemia|Peripheral Vascular Diseases

Phase 2: Dyslipidemia|Hypercholesterolemia|Rhinitis, Allergic, Seasonal|Asthma|Flushing

Phase 1: Hypercholesterolemia|Hyperlipidemia|Type 2 Diabetes|Dyslipidemia|Hyperlipoproteinemia Type II|Rosacea

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NILACH

P4

Terminated

Atherosclerosis

2014-07-01

MK-0524A-119

N/A

Terminated

Hypercholesterolemia|Dyslipidemia

2013-05-01

2011-000755-17

P3

Terminated

Coronary Disease

2013-03-08

MK-0524A-133

P3

Terminated

Hypercholesterolemia|Dyslipidemia

2013-02-26

Recent News Events